ORTX News and Press, Orchard Therapeutics plc From 01/05/23

BOSTON and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OTL-203, a hematopoietic stem cell (HSC) gene therapy ...

Summary Orchard Therapeutics is one of these tickers that, after losing approximately 65% of its value over the past twelve months, has a market cap of around $55M. ORTX has a price-to-book of 0.45 and an enterprise value of about -$32M. What is more, ORTX has a price-to-sales of 2.72x....

Orchard Therapeutics PLC (ORTX) Q1 2022 Earnings Conference Call May 12, 2022, 08:00 ET Company Participants Bobby Gaspar - CEO Braden Parker - Chief Commercial Officer Frank Thomas - President & COO Leslie Meltzer - Chief Medical Officer Conference Call Participants Brendan Smith - Cowen...

Orchard Therapeutics press release (NASDAQ:ORTX): Q1 GAAP EPS of -$0.35 misses by $0.10. Revenue of $5.52M beats by $1.48M. The company expects that its existing cash, cash equivalents and investments of $199M will fund its anticipated operating, debt service and capital expenditure requireme...

Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy ® access and reimbursement expanding with agreements now signed in three major European markets recognizing its clinical value OTL-200 U.S. BLA fil...

Orchard Therapeutics (NASDAQ:ORTX) is scheduled to announce Q1 earnings results on Thursday, May 12th, before market open. The consensus EPS Estimate is -$0.24 (+22.6% Y/Y) and the consensus Revenue Estimate is $4.04M (+304.0% Y/Y). Over the last 3 months, EPS estimates have seen 4 upward rev...

AADI,ACHR,ACTG,ADN,AEG,OTCPK:ALIZF,ALT,AMTX,OTCPK:ARNGF,ARQQ,ATY,BAM,BGRY,BKKT,BT,CAMT,CASI,CORR,CPG,CYBR,CYXT,DAVA,DCBO,DRIO,EMAN,EURN,GENI,HIMX,OTCPK:HNHAF,HUT,IS,KNOP,KT,LQDA,MGIC,OTCPK:MKGAF,ML,MOGO,MTNB,NETI,NICE,OTCPK:NSANY,NVMI,ORTX,PCT,OTCPK:PEYUF,OTCQX:QTRHF,RDCM,OTCPK:RWEOY,SCYX,SFL...

BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 1...

BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022, at 8:00 a.m. ET to review business updates and its first quarter 20...

BOSTON and LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with Gesetzliche Krankenversicherung Spitzenverband (GKV-SV) which will result in reimbursed access to Libmeldy ® (atid...